CN105901720A - Health care food capable of lowering alcoholic liver injury harm and preparation method thereof - Google Patents
Health care food capable of lowering alcoholic liver injury harm and preparation method thereof Download PDFInfo
- Publication number
- CN105901720A CN105901720A CN201610326001.4A CN201610326001A CN105901720A CN 105901720 A CN105901720 A CN 105901720A CN 201610326001 A CN201610326001 A CN 201610326001A CN 105901720 A CN105901720 A CN 105901720A
- Authority
- CN
- China
- Prior art keywords
- fine powder
- standby
- liver injury
- preparation
- alcoholic liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 18
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 12
- 230000006378 damage Effects 0.000 title claims abstract description 11
- 235000013305 food Nutrition 0.000 title abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 241000222336 Ganoderma Species 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 235000013402 health food Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 4
- 239000005022 packaging material Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000009512 pharmaceutical packaging Methods 0.000 claims description 2
- 238000007781 pre-processing Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims 1
- 238000012946 outsourcing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 6
- 240000006079 Schisandra chinensis Species 0.000 abstract description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 235000014899 silybin Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a health care food capable of lowering the alcoholic liver injury harm and a preparation method thereof, and provides the preparation method of the health care food. Experiments in the pharmacological aspects show that the health care food is a medicine composition formed by reasonably matching schisandra chinensis and lucid ganoderma powder according to a proportion being 2:1; the effect of lowering the alcoholic liver injury harm is achieved.
Description
Technical field
The invention discloses a kind of health food contributing to reduction alcoholic liver injury harm and preparation method thereof, belong to technical field of health care food.
Background technology
" elder brother's lofty board five spirit sheet " is to utilize a kind of novel healthy food developed in our province Changbai Mountain genuine traditional Chinese medicine material Radix Schisandrae Bicoloris (Schisandra chinensis.) and Polyporaceae Ganoderma fungus red ganoderma (G.lucidum karst) reasonable compatibility, develops by " contributing to reducing alcoholic liver injury harm " effect.Its preparation method and auxiliary reduce the purposes of alcoholic liver injury harm and there is not yet application.
Summary of the invention
The invention discloses a kind of health food " elder brother's lofty board five spirit sheet " contributing to reducing alcoholic liver injury harm and preparation method thereof.
The preparation method of embodiment elder brother's lofty board five spirit sheet
The preparation technology of preparation
1) preprocessing raw material and auxiliary material
1. Fructus Schisandrae Chinensis, pulverizes, and 80% alcohol reflux three times is concentrated to give extractum Fructus Schisandrae Chinensis extrat.
2. beta-schardinger dextrin-, crosses 80 mesh sieves, obtains fine powder A, standby.
3. Ganoderma starch mixture, crosses 80 mesh sieves, obtains fine powder B, standby.
4. hard magnesium, crosses 80 mesh sieves, obtains fine powder C, standby.
5. polyvinylpyrrolidone (PVP) is transferred to clean area after removing outer package, makees solvent with 50% ethanol and is configured to the PVP solution of 10%, standby.
2) dispensing: by supplementary material and consumption requirement dispensing.
3) mixing: take Fructus Schisandrae Chinensis extrat and mix with fine powder A, take fine powder B and mix mutually with the mixture of fine powder A and Fructus Schisandrae Chinensis extrat gained, then total mixture is put in refrigerator freezing, mixer mixes 20min, mix homogeneously afterwards, obtains total mixed powder.
4) pelletize, be dried: take above-mentioned total mixed powder, spray the PVP solution of 10%, cross 10 mesh sieves and pelletize, obtain wet granular.Wet granular is dried under the conditions of 50 DEG C-60 DEG C, crosses 14 mesh sieve granulate, obtain dry granule, standby.
5) always mix: above-mentioned dry granule is put with fine powder C mixer mixes 10min, obtain total hybrid particles.
6) tabletting: total hybrid particles is put and carries out tabletting on tablet machine, regulation tablet weight 0.50g/ sheet, element sheet, standby.
7) pack, check, finished product warehouse-in: tablet is bottled, 100 slices/bottle, and interior packaging material is oral administration solid medicinal high density ethylene bottle, meets the requirement regulation of national drug packaging material standard YBB00122002.After general production district carries out outer package, finished product randomization quality inspection, qualified rear finished product is put in storage again.
The spirit sheet protective effect to alcohol-induced liver injury in rats of test example 1 elder brother's lofty board five
1 materials and methods
1.1 Animals Male Wistar rats 150, body weight 180～220g, by the animal experimental center supply of preclinical medicine institute of Jilin University, the quality certification number: SCXK-(lucky) 2007-0003.Animal feeding in ventilation Animal House, room temperature (20 ± 2) DEG C, ad lib and drinking-water.
1.2 medicine elder brother's lofty board five spirit sheets, are provided by Jilin University " Jilin Province's Ganoderma standardized planting and development engineering research center ", and every 100g contains: deoxyschizandrin, B prime and alcohol first 0.2g；Total triterpene (in terms of ursolic acid) 0.18g.Silybin Capsules is produced by Tianjin Tasly Pharmaceutical Co., Ltd, lot number: 20120721, is configured to suspension with 0.5% sodium carboxymethyl cellulose；T-CHOL (TC), triglyceride (TG), very low density lipoprotein (VLDL) (VLDL), free fatty (FFA), malonaldehyde (MDA), superoxide dismutase (SOD) glutamic oxaloacetic transaminase, GOT (ALT) and glutamate pyruvate transaminase (AST) testing cassete are built up Bioengineering Research Institute by Nanjing and provide.
1.3 method
Male Wistar rat 150, adaptability is raised one week, taking 12 rats is normal group, remaining rat sets up alcoholic liver injury model: within the 1st～4 week, gavage gives 40% Chinese liquor 8g/kg, within 5th～8 week, give 50% Chinese liquor 9g/kg, within the 9th～16 week, give 50% Chinese liquor 10g/kg [ethanol dosage (g)=ethanol volume (mL) × prewired alcohol concentration (%) × ethanol density (0.8g/mL)].Within 9th week, rat model divides 5 groups at random according to body weight: model group, five spirit sheets (0.25,0.5,1.0g/kg) group level positive drug silibinin (80mg/kg) groups, respectively organizing gavage respectively after packet and give relative medicine, normal and model group gives the sodium carboxymethyl cellulose of same volume 0.5%.After being administered 8 weeks, chloral hydrate anesthesia, abdominal aortic blood, separate serum, detection TC, TG, VLDL, FFA, MDA content and SOD, AST, ALT activity；After abdominal aortic blood, open abdominal cavity and take out liver, remove surrounding connective tissue, blot with filter paper after brine, electronic balance weighing liver weight in wet base, calculates liver index (liver index=liver weight in wet base (g)/body weight (g) × 100%)；Weigh hepatic tissue 1.0g, put into small beaker.Measure the pre-cold saline of hepatic tissue blocking weight 9 times, take and wherein 2/3 put into small beaker, shred hepatic tissue blocking with eye scissors as early as possible.The hepatic tissue shredded is poured in homogenizer with normal saline, after remaining 1/3 normal saline flushing small beaker, together pours homogenizer into, be fully ground, prepare 10% liver tissue homogenate, with 3000rmp rotating speed, centrifugal 20min, take supernatant standby.MDA content and SOD activity is measured according to MDA and SOD test kit description.
1.4 statistical analysis
Experimental data SPSS 10.0 statistical software processes, with mean ± standard deviationRepresenting, comparing employing variance analysis between each group, p < 0.05 thinks there is significant difference.
2 results
The 2.1 5 spirit sheet impacts on alcohol-induced liver injury in rats model lipid metabolism
Compare with normal group, model group rats serum TC, TG, VLDL and FFA content are all increased significantly (P < 0.05 or P < 0.01), compare with model group, five spirit sheet 4g/kg groups and silibinin group all can substantially reduce Serum TC, TG, VLDL and FFA content (P < 0.05 or P < 0.01), five spirit sheet 2g/kg groups can substantially reduce rat blood serum TG, VLDL and FFA content (P < 0.05), the results are shown in Table 1.
Table 1 five spirit sheet on the impact of AFLD rat lipid metabolism (N=10)
Compare with normal group,#P<0.05,##P<0.01；Compare with model group,*P<0.05,**P<0.01
The 2.2 5 spirit sheet impacts on alcohol-induced liver injury in rats model free radical
Comparing with normal group, model group rats serum and Liver MDA are significantly raised, and SOD activity substantially reduces (P < 0.01)；Comparing with model group, five spirit sheet 2,4g/kg groups all can substantially reduce rat blood serum and Liver MDA, increasing serum and hepatic tissue SOD activity (P < 0.05 or P < 0.01), the results are shown in Table 2.
Table 2 five spirit sheet on the impact of AFLD free radicals in rats (N=10)
Compare with normal group,#P<0.05,##P<0.01；Compare with model group,*P<0.05,**P<0.01
The 2.3 5 spirit sheet impacts on alcohol-induced liver injury in rats model Liver enzyme
Compare with normal group, model group AST, ALT activity significantly raised (P < 0.05 or P < 0.01)；Comparing with model group, five spirit sheets 2,4g/kg dosage group and silibinin group all can substantially reduce serum alt activity (P<0.05 or P<0.01), and AST activity has reduction trend (P>0.05), and result is shown in 3.
Table 3 five spirit sheet on the impact of AFLD rat blood serum liver enzyme (N=10)
Compare with normal group,#P<0.05,##P<0.01；Compare with model group,*P<0.05,**P<0.01
The 2.4 5 spirit sheet impacts on alcohol-induced liver injury in rats model liver index
Compared with normal group, model group rats liver index significantly raised (P < 0.001), compare with model group, five spirit sheets are not improved effect to rats'liver index, and result is shown in 4.
Table 4 five spirit sheet on the impact of alcohol-induced liver injury in rats model liver index (N=10)
###P<0.001compared with Normal 。
Claims (3)
1. the health food reducing alcoholic liver injury harm, it is characterised in that by including the former of following portions by weight proportioning
Material is made: Radix Schisandrae Bicoloris and Ganoderma powder are by 2:1 proportions.
2. reduce a preparation method for the health food of alcoholic liver injury harm, comprise the following steps:
1) preprocessing raw material and auxiliary material
1. Fructus Schisandrae Chinensis, pulverizes, and 80% alcohol reflux three times is concentrated to give extractum Fructus Schisandrae Chinensis extrat；
2. beta-schardinger dextrin-, crosses 80 mesh sieves, obtains fine powder A, standby；
3. Ganoderma starch mixture, crosses 80 mesh sieves, obtains fine powder B, standby；
4. hard magnesium, crosses 80 mesh sieves, obtains fine powder C, standby；
5. polyvinylpyrrolidone (PVP) is transferred to clean area after removing outer package, does solvent preparation with 50% ethanol
Become the PVP solution of 10%, standby；
2) dispensing: by supplementary material and consumption requirement dispensing；
3) mixing: take Fructus Schisandrae Chinensis extrat and mix with fine powder A, takes fine powder B and fine powder A and Fructus Schisandrae Chinensis extrat gained
Mixture mixes mutually, then is put by total mixture in refrigerator freezing, mixes 20min, mix homogeneously afterwards, obtain in mixer
Total mixed powder；
4) pelletize, be dried: take above-mentioned total mixed powder, spray the PVP solution of 10%, cross 10 mesh sieves and pelletize, obtain wet granular；
Wet granular is dried under the conditions of 50 DEG C-60 DEG C, crosses 14 mesh sieve granulate, obtain dry granule, standby；
5) always mix: above-mentioned dry granule is put with fine powder C mixer mixes 10min, obtain total hybrid particles；
6) tabletting: total hybrid particles is put and carries out tabletting on tablet machine, regulation tablet weight 0.50g/ sheet, element sheet, standby；
7) pack, check, finished product warehouse-in: tablet is bottled, and 100 slices/bottle, interior packaging material is oral administration solid medicinal high density second
Alkene bottle, meets the requirement regulation of national drug packaging material standard YBB00122002, carries out outsourcing in the general district that produces
After dress, finished product randomization quality inspection, qualified rear finished product is put in storage again.
3. the health food described in claim 1 contributes to reducing the use in alcoholic liver injury harm health food in preparation
On the way.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610326001.4A CN105901720A (en) | 2016-05-17 | 2016-05-17 | Health care food capable of lowering alcoholic liver injury harm and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610326001.4A CN105901720A (en) | 2016-05-17 | 2016-05-17 | Health care food capable of lowering alcoholic liver injury harm and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105901720A true CN105901720A (en) | 2016-08-31 |
Family
ID=56749240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610326001.4A Pending CN105901720A (en) | 2016-05-17 | 2016-05-17 | Health care food capable of lowering alcoholic liver injury harm and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105901720A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108618148A (en) * | 2017-03-21 | 2018-10-09 | 江苏海睿生物科技有限公司 | A kind of health food to alcoholic liver injury with defencive function |
| CN109793825A (en) * | 2019-03-22 | 2019-05-24 | 中国农业科学院特产研究所 | Rainbow conk Fructus Schisandrae Chinensis extractum and its preparation method and application |
-
2016
- 2016-05-17 CN CN201610326001.4A patent/CN105901720A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108618148A (en) * | 2017-03-21 | 2018-10-09 | 江苏海睿生物科技有限公司 | A kind of health food to alcoholic liver injury with defencive function |
| CN109793825A (en) * | 2019-03-22 | 2019-05-24 | 中国农业科学院特产研究所 | Rainbow conk Fructus Schisandrae Chinensis extractum and its preparation method and application |
| CN109793825B (en) * | 2019-03-22 | 2022-04-12 | 中国农业科学院特产研究所 | Coriolus versicolor and schisandra chinensis extract and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102631377B (en) | Cordyceps sinensis freeze-dried nano powder tablet and preparation method thereof | |
| US9138449B2 (en) | Medicinal composition for liver diseases | |
| CN102885306A (en) | Health-care food composite with function of assisting in reducing blood fat and preparation method thereof | |
| CN103479833B (en) | Hepatoprotective composition as well as preparation method and application thereof | |
| CN104644694A (en) | Preparation method of ultramicro spirulina powder as well as preparation and application thereof | |
| CN114028533A (en) | Composition with functions of dispelling effects of alcohol and protecting liver and preparation method and application thereof | |
| CN105901720A (en) | Health care food capable of lowering alcoholic liver injury harm and preparation method thereof | |
| CN101019644B (en) | Health food with auxiliary function of protecting liver against chemical damage and its prepn | |
| CN101019898B (en) | Crushing method and preparation of aweto | |
| CN1883537A (en) | Compound Chinese medicinal preparation for treating hypertension and hyperlipemia and preparation method thereof | |
| CN108785476A (en) | The preparation method and application of solid composite containing A Sayi fruits and Herba Cistanches | |
| CN1994353A (en) | A superfine powdered Chinese medicinal composition and preparation method thereof | |
| CN109806320A (en) | A kind of Fu tea extraction containing coronoid process dissipate capsule bacterium living, preparation method and applications | |
| CN1733109A (en) | Soft capsule for treating coronary disease and process for preparing the same | |
| CN1686184A (en) | Soft capsule using dendrobium as raw material and its preparation method | |
| CN102552139A (en) | Oligomeric proantho cyanidins self-emulsifying system composition and application thereof | |
| CN107997170B (en) | Composition with blood fat reducing function and preparation method thereof | |
| RU2796502C1 (en) | Cellulose-containing composition, tablet and tablet with intraoral disintegration | |
| CN1772234A (en) | Chinese medicine prepn for treating women's disease and its prepn | |
| CN1883644A (en) | Chinese medicinal tablet for treating gynecological disease and preparation process thereof | |
| CN104352534A (en) | Poria peel total-triterpene dispersible tablet and preparation method thereof | |
| CN109316565A (en) | A kind of blood-fat reducing composition and its preparation method and application | |
| CN1817359A (en) | Chinese medicinal preparation for treating gynecopathy and production thereof | |
| Okolie et al. | Formulation design and evaluation of the physicotechnical and hypoglycaemic properties of tablets containing Dioscorea dumetorum fraction in alloxanized diabetic rats | |
| CN102008565A (en) | Medicine composition for treating ulcerative colitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160831 |
|
| WD01 | Invention patent application deemed withdrawn after publication |